These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C; JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444 [TBL] [Abstract][Full Text] [Related]
5. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202 [TBL] [Abstract][Full Text] [Related]
6. COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial. Dubois C; Bennett J; Dens J; De Cock D; Desmet W; Belmans A; Ughi GJ; Sinnaeve P; Vrolix M; D'hooge J; Adriaenssens T EuroIntervention; 2016 Apr; 11(13):1457-67. PubMed ID: 25947278 [TBL] [Abstract][Full Text] [Related]
7. Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. Ferenc M; Gick M; Comberg T; Rothe J; Valina C; Toma A; Löffelhardt N; Hochholzer W; Riede F; Kienzle RP; Achtari A; Neumann FJ Eur Heart J; 2016 Dec; 37(45):3399-3405. PubMed ID: 27578807 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study. Erglis A; Kumsars I; Niemelä M; Kervinen K; Maeng M; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Mäkikallio T; Ylitalo K; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Syvänne M; Helqvist S; Kjell N; Wiseth R; Aarøe J; Puhakka M; Thuesen L; Circ Cardiovasc Interv; 2009 Feb; 2(1):27-34. PubMed ID: 20031690 [TBL] [Abstract][Full Text] [Related]
9. Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study. Chen SL; Xu B; Han YL; Sheiban I; Zhang JJ; Ye F; Kwan TW; Paiboon C; Zhou YJ; Lv SZ; Dangas GD; Xu YW; Wen SY; Hong L; Zhang RY; Wang HC; Jiang TM; Wang Y; Chen F; Yuan ZY; Li WM; Leon MB J Am Coll Cardiol; 2013 Apr; 61(14):1482-8. PubMed ID: 23490040 [TBL] [Abstract][Full Text] [Related]
10. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB; EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298 [TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry. Sgueglia GA; Burzotta F; Trani C; Todaro D; Talarico GP; Niccoli G; Porto I; Leone AM; Coluccia V; Mazzari MA; Mongiardo R; Schiavoni G; Crea F Catheter Cardiovasc Interv; 2011 Mar; 77(4):503-9. PubMed ID: 20602477 [TBL] [Abstract][Full Text] [Related]
12. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA; JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545 [TBL] [Abstract][Full Text] [Related]
14. Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study. Džavík V; Kaul U; Guagliumi G; Chevalier B; Smits PC; Stuteville M; Li D; Sudhir K; Grube E Catheter Cardiovasc Interv; 2013 Sep; 82(3):E163-72. PubMed ID: 23225766 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859 [TBL] [Abstract][Full Text] [Related]
17. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959 [TBL] [Abstract][Full Text] [Related]
18. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661 [TBL] [Abstract][Full Text] [Related]
19. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry. Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G; EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]